<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04572308</url>
  </required_header>
  <id_info>
    <org_study_id>CD7 CAR-T for T-ALL/T-LBL</org_study_id>
    <nct_id>NCT04572308</nct_id>
  </id_info>
  <brief_title>Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells</brief_title>
  <official_title>Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Senlang Biotechnology Inc., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hebei Senlang Biotechnology Inc., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open, single-arm, clinical study to evaluate efficacy and safety of anti CD7 CAR-T&#xD;
      cell in the treatment of relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL)&#xD;
      and lymphoblastic lymphoma (TLBL).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The CARs consist of an anti-CD7 single-chain variable fragment（scFv）, a portion of the human&#xD;
      CD137（4-1BB） molecule, and the intracellular component of the human CD3ζ molecule. Prior to&#xD;
      CAR-T cell infusion, the patients will be subjected to preconditioning treatment. After CAR-T&#xD;
      cell infusion, the patients will be evaluated for adverse reactions and efficacy.&#xD;
&#xD;
      The Main research objectives:&#xD;
&#xD;
      To evaluate the safety and efficacy of CD7 CAR-T cells in patients with relapsed or&#xD;
      refractory T-ALL/LBL&#xD;
&#xD;
      The Secondary research objectives:&#xD;
&#xD;
      To investigate the cytokinetic characteristics of CD7 CAR-T cells in patients with relapsed&#xD;
      or refractory T-ALL/LBL&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Actual">May 30, 2021</completion_date>
  <primary_completion_date type="Actual">May 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Incidence and severity of adverse events</measure>
    <time_frame>First 1 month post CAR-T cells infusion</time_frame>
    <description>To evaluate the possible adverse events occurred within the first one month after CD7 CAR-T infusion, including the incidence and severity of symptoms such as cytokine release syndrome and neurotoxicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy: Remission Rate</measure>
    <time_frame>3 months post CAR-T cells infusion</time_frame>
    <description>Remission Rate including complete remission(CR)、CR with incomplete blood count recovery(CRi)、partial remission(PR), No remission(NR), overall remission (OR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>duration of response (DOR)</measure>
    <time_frame>24 months post CAR-T cells infusion</time_frame>
    <description>duration of response (DOR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: progression-free survival (PFS)</measure>
    <time_frame>24 months post CAR-T cells infusion</time_frame>
    <description>progression-free survival (PFS) time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CAR-T proliferation</measure>
    <time_frame>3 months post CAR-T cells infusion</time_frame>
    <description>the copy number of CD7 CAR- T cells in the genomes of PBMC by qPCR method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CAR-T proliferation</measure>
    <time_frame>3 months post CAR-T cells infusion</time_frame>
    <description>percentage of CD7 CAR- T cells measured by flow cytometry method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine release</measure>
    <time_frame>First 1 month post CAR-T cells infusion</time_frame>
    <description>Cytokine( IL-6,IL-10,IFN-γ,TNF-α ) concentration (pg/mL) by flow cytometry method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) indicators:</measure>
    <time_frame>Long time</time_frame>
    <description>the peak concentration of Senl-T7 CAR-T cells amplified in the peripheral blood (Cmax, detected by flow cytometry and qPCR); the time taken to reach the peak concentration (Tmax), and the persistent time of the Senl-T7 CAR-T cells in vivo in patients;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic (PD) indicators:</measure>
    <time_frame>First 1 month post CAR-T cells infusion</time_frame>
    <description>the pharmacodynamic change in the clearance of peripheral blood CD7+ cells and the release of the cytokines at each observation time point</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>T-cell Acute Lymphoblastic Leukemia/Lymphoma</condition>
  <arm_group>
    <arm_group_label>CD7 CAR-T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with CD7 CAR-T cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD7 CAR-T</intervention_name>
    <description>Patients will be treated with CD7 CAR-T cells&#xD;
Biological: CD7 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;</description>
    <arm_group_label>CD7 CAR-T</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of refractory or relapsed T-cell acute lymphoblastic leukemia (T-ALL) or&#xD;
             lymphoblastic lymphoma (T-LBL) according to the NCCN 2019.V2 Guideline. Refractory&#xD;
             T-ALL is defined as a patient who has failed to achieve complete remission after&#xD;
             induction therapy. Relapsed T-ALL is defined as the reappearance of blasts (5%) in&#xD;
             either peripheral blood or bone marrow. Patients whose tumor burden &gt;5% blasts, or who&#xD;
             have persistent positive minimal residual disease (MRD), or have reappearance of&#xD;
             extramedullary lesions are also considered eligible.&#xD;
&#xD;
          2. CD7-positive tumor (≥70% CD7 positive blasts by flow cytometry or immunohistochemistry&#xD;
             (tissue) assessed by a CLIA certified Flow Cytometry/Pathology laboratory). tumors&#xD;
             burden &gt;5%,or MRD+， or new extramedullary lesions reappeared.&#xD;
&#xD;
          3. Life expectancy greater than 12 weeks&#xD;
&#xD;
          4. KPS or Lansky score≥60&#xD;
&#xD;
          5. HGB≥70g/L&#xD;
&#xD;
          6. oxygen saturation of blood&gt;90%&#xD;
&#xD;
          7. Total bilirubin (TBil)≤3 × upper limit normal, aspartate aminotransferase (AST) and&#xD;
             alanine aminotransferase (ALT) ≤ 5×upper limit of normal&#xD;
&#xD;
          8. Informed consent explained to, understood by and signed by patient/guardian.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any of the following cardiac criteria: Atrial fibrillation/flutter; Myocardial&#xD;
             infarction within the last 12 months; Prolonged QT syndrome or secondary prolonged QT,&#xD;
             per investigator discretion. Cardiac echocardiography with LVSF (left ventricular&#xD;
             shortening fraction)&lt;30% or LVEF(left ventricular ejection fraction)&lt;50%; or&#xD;
             clinically significant pericardial effusion. Cardiac dysfunction NYHA(New York Heart&#xD;
             Association) III or IV (Confirmation of absence of these conditions on echocardiogram&#xD;
             within 12 months of treatment)&#xD;
&#xD;
          2. Has an active GvHD;&#xD;
&#xD;
          3. Has a history of severe pulmonary function damaging;&#xD;
&#xD;
          4. With other tumors which is/are in advanced malignant and has/have systemic metastasis;&#xD;
&#xD;
          5. Severe or persistent infection that cannot be effectively controlled；&#xD;
&#xD;
          6. Presence of severe autoimmune diseases or immunodeficiency disease;&#xD;
&#xD;
          7. Patients with active hepatitis B or hepatitis C([HBVDNA+]or [HCVRNA+]);&#xD;
&#xD;
          8. Patients with HIV infection or syphilis infection;&#xD;
&#xD;
          9. Has a history of serious allergies to biological products (including antibiotics);&#xD;
&#xD;
         10. Clinically significant viral infection or uncontrolled viral reactivation of&#xD;
             EBV(Epstein-Barr virus), CMV(cytomegalovirus), ADV(adenovirus), BK-virus, or HHV(human&#xD;
             herpesvirus)-6.&#xD;
&#xD;
         11. Presence of any symtomatic CNS disorder such as an uncontrolled seizure disorder,&#xD;
             cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune&#xD;
             disease with CNS involvement;&#xD;
&#xD;
         12. Received allogeneic hematopoietic stem cell transplantation within 6 months;&#xD;
&#xD;
         13. Being pregnant and lactating or having pregnancy within 12 months;&#xD;
&#xD;
         14. Any situations that the researchers believe will increase the risks for the subject or&#xD;
             affect the results of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hebei yanda Ludaopei Hospital</name>
      <address>
        <city>Yanda</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 27, 2020</study_first_submitted>
  <study_first_submitted_qc>September 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2020</study_first_posted>
  <last_update_submitted>June 23, 2021</last_update_submitted>
  <last_update_submitted_qc>June 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T-ALL，T-LBL , CD7，CAR-T</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

